文献速递妇科生殖医学

紧急避孕方案1年内的成本效果比较

Cost-effectiveness of emergency contraception options over 1 year.
PubMed 文献 · Am J Obstet Gynecol · 2018-02-01

该研究采用马尔可夫模型模拟1000名寻求紧急避孕的女性,从美国支付方角度比较醋酸乌利司他、口服左炔诺孕酮、铜宫内节育器及口服左炔诺孕酮加同日左炔诺孕酮宫内节育器4种方案1年内的成本与妊娠结局。铜宫内节育器在多数模型迭代中(63.9%)最具成本效果,与醋酸乌利司他相比每多预防1例妊娠多花费1957美元。

要点

  • 铜宫内节育器在63.9%的模型迭代中为最具成本效果的紧急避孕方案。
  • 与醋酸乌利司他相比,铜宫内节育器每多预防1例妊娠多花费1957美元。
  • 铜宫内节育器成本升高时,口服左炔诺孕酮加同日左炔诺孕酮宫内节育器成为最具成本效果方案。

核心结论

  • 1年内铜宫内节育器是目前最具成本效果的紧急避孕方案。
  • 政策制定者和医疗保险机构应考虑,当寻求紧急避孕的女性能够及时获得最符合其个人偏好和需求的避孕方法时,可能带来长期节省;这需要消除障碍并促进在紧急避孕就诊时获取宫内节育器。

研究设计与样本

  • 采用马尔可夫模型模拟1000名寻求紧急避孕的女性,从美国支付方角度比较4种紧急避孕策略1年内的成本和妊娠结局。
  • 成本以2017年美元计,每28天周期估计紧急避孕失败及后续避孕使用导致的妊娠结局(活产、异位妊娠、自然流产或人工流产)。
  • 模型输入来自已发表文献和国家来源。
  • 若增量成本效果比(即每多预防1例妊娠的成本)低于美国妊娠结局的加权平均成本(5167美元),则认为该紧急避孕策略具有成本效果。
  • 增量成本效果比和成为最具成本效果紧急避孕策略的概率通过1000次概率模型迭代计算。

主要发现

  • 在1000名寻求紧急避孕的女性中,模型估计醋酸乌利司他的直接医疗成本为1,228,000美元、非意愿妊娠137例。
  • 口服左炔诺孕酮的直接医疗成本为1,279,000美元、非意愿妊娠150例。
  • 铜宫内节育器的直接医疗成本为1,376,000美元、非意愿妊娠61例。
  • 口服左炔诺孕酮加同日左炔诺孕酮宫内节育器的直接医疗成本为1,558,000美元、非意愿妊娠63例。
  • 铜宫内节育器在多数(63.9%)模型迭代中为最具成本效果的紧急避孕策略,与醋酸乌利司他相比每多预防1例妊娠多花费1957美元。

关键数值与推荐

  • 成本效果阈值:增量成本效果比低于美国妊娠结局加权平均成本5167美元。
  • 铜宫内节育器在63.9%的模型迭代中为最具成本效果策略。
  • 铜宫内节育器与醋酸乌利司他相比的增量成本效果比为每多预防1例妊娠1957美元。
  • 模型估计对铜宫内节育器成本变化最敏感:铜宫内节育器成本升高时,口服左炔诺孕酮加同日左炔诺孕酮宫内节育器成为最具成本效果方案。
  • 模型估计对活产成本变化敏感:活产成本降低时,醋酸乌利司他成为最具成本效果方案。

临床怎么用

  • 政策制定者和医疗保险机构应考虑,当寻求紧急避孕的女性能够及时获得最符合其个人偏好和需求的避孕方法时,可能带来长期节省;这需要消除障碍并促进在紧急避孕就诊时获取宫内节育器。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The copper intrauterine device is the most effective form of emergency contraception and can also provide long-term contraception. The levonorgestrel intrauterine device has also been studied in combination with oral levonorgestrel for women seeking emergency contraception. However, intrauterine devices have higher up-front costs than oral methods, such as ulipristal acetate and levonorgestrel. Health care payers and decision makers (eg, health care insurers, government programs) with financial constraints must determine if the increased effectiveness of intrauterine device emergency contraception methods are worth the additional costs. OBJECTIVE: We sought to compare the cost-effectiveness of 4 emergency contraception strategies-ulipristal acetate, oral levonorgestrel, copper intrauterine device, and oral levonorgestrel plus same-day levonorgestrel intrauterine device-over 1 year from a US payer perspective. STUDY DESIGN: Costs (2017 US dollars) and pregnancies were estimated over 1 year using a Markov model of 1000 women seeking emergency contraception. Every 28-day cycle, the model estimated the predicted number of pregnancy outcomes (ie, live birth, ectopic pregnancy, spontaneous abortion, or induced abortion) resulting from emergency contraception failure and subsequent contraception use. Model inputs were derived from published literature and national sources. An emergency contraception strategy was considered cost-effective if the incremental cost-effectiveness ratio (ie, the cost to prevent 1 additional pregnancy) was less than the weighted average cost of pregnancy outcomes in the United States ($5167). The incremental cost-effectiveness ratios and probability of being the most cost-effective emergency contraception strategy were calculated from 1000 probabilistic model iterations. One-way sensitivity analyses were used to examine uncertainty in the cost of emergency contraception, subsequent contraception, and pregnancy outcomes as well as the model probabilities. RESULTS: In 1000 women seeking emergency contraception, the model estimated direct medical costs of $1,228,000 and 137 unintended pregnancies with ulipristal acetate, compared to $1,279,000 and 150 unintended pregnancies with oral levonorgestrel, $1,376,000 and 61 unintended pregnancies with copper intrauterine devices, and $1,558,000 and 63 unintended pregnancies with oral levonorgestrel plus same-day levonorgestrel intrauterine device. The copper intrauterine device was the most cost-effective emergency contraception strategy in the majority (63.9%) of model iterations and, compared to ulipristal acetate, cost $1957 per additional pregnancy prevented. Model estimates were most sensitive to changes in the cost of the copper intrauterine device (with higher copper intrauterine device costs, oral levonorgestrel plus same-day levonorgestrel intrauterine device became the most cost-effective option) and the cost of a live birth (with lower-cost births, ulipristal acetate became the most cost-effective option). When the proportion of obese women in the population increased, the copper intrauterine device became even more most cost-effective. CONCLUSION: Over 1 year, the copper intrauterine device is currently the most cost-effective emergency contraception option. Policy makers and health care insurance companies should consider the potential for long-term savings when women seeking emergency contraception can promptly obtain whatever contraceptive best meets their personal preferences and needs; this will require removing barriers and promoting access to intrauterine devices at emergency contraception visits.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bellows BK, Tak CR, Sanders JN, et al. Cost-effectiveness of emergency contraception options over 1 year. Am J Obstet Gynecol. 2018. PMID: 29409847. doi:10.1016/j.ajog.2018.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。